劉同博

[關(guān)鍵詞] 水飛薊賓;恩替卡韋;乙肝肝硬化;老年患者;氧化應(yīng)激反應(yīng);肝纖維化

[中圖分類號] R512.62? ? ? ? ? [文獻(xiàn)標(biāo)識碼] B? ? ? ? ? [文章編號] 1673-9701（2021）25-0110-04

Value analysis of silybin combined with entecavir in treating elderly patients with hepatitis B cirrhosis

LIU Tongbo

Department of Pharmacy， Jiamusi Infectious Disease Hospital in Heilongjiang Province， Jiamusi? ?154007， China

[Abstract] Objective To investigate the clinical efficacy of silybin combined with entecavir in the treatment of elderly patients with hepatitis B cirrhosis （HBC）. Methods A total of 129 elderly patients with HBC admitted to our hospital from March 2019 to April 2020 who met the requirement of this research were selected. They were divided into the observation group （n=64） and the control group （n=65） according to random number table method. The observation group was treated with silybin and entecavir， while the control group was treated with entecavir alone. The clinical efficacy， alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， procollagen type Ⅲ （PC Ⅲ）， type Ⅳ precollagen （Ⅳ-C）， nitric oxide （NO）， malondialdehyde （MDA）， the negative conversion rate of HBV-DNA and the negative conversion rate of HBeAg were compared between the two groups. Results The total effective rate of clinical treatment was significantly higher in the observation group （93.75%） than that in the control group （76.92%）， with statistically significant difference（P<0.05）. The levels of ALT and AST were significantly better in the observation group than those in the control group after treatment（P<0.05）. After treatment， PC Ⅲ and Ⅳ-C were better in the observation group than those in the control group（P<0.05）. The levels of NO and MDA were better in the observation group than those in the control group after treatment（P<0.05）. The negative rate of HBV-DNA and HBeAg were higher in the observation group （93.75% and 46.88%） than those in the control group （78.46% and 24.62%） after treatment， with statistically significant differences （P<0.05）. Conclusion Silybin combined with entecavir has a good clinical effect in the treatment of elderly patients with HBC， which can improve liver function and liver fibrosis， and reduce oxidative stress reaction on this basis. It has obvious advantages in the treatment of elderly patients.

[Key words] Silybin; Entecavir; Hepatitis B cirrhosis; Elderly patients; Oxidative stress reaction; Hepatic fibrosis